Respiratory technology · In development
Transforming Inhalation.
Rethinking Respiratory Health.
LungSphere is developing a new nicotine-free inhalation platform designed to bridge the gap between human behaviour and respiratory care.
01 — The Problem
Two persistent challenges at the intersection of behaviour and the lungs.
Smoking cessation remains difficult
Many people who want to stop smoking find it hard to do so. Existing approaches often address nicotine dependence without fully engaging the habitual and sensory aspects of inhalation.
Inhaled therapy depends on the user
Respiratory treatments rely on correct inhaler technique and consistent use. Usability and adherence can limit how well inhaled medicines perform in everyday life.
02 — Our Approach
A developing platform built on three principles.
A more engaging inhalation experience
Designing an experience that respects the behavioural and sensory side of inhalation, not only the pharmacology.
Controlled aerosol generation and airflow
Pursuing precise, repeatable control over how an aerosol is formed and carried with each breath.
Future respiratory drug delivery
Exploring whether the same platform could one day support delivery of therapeutic formulations to the lungs.
These are development goals. They have not been demonstrated in clinical studies.
03 — The Technology
Where aerosol science, airflow and formulation meet.
Aerosol generation
Forming an aerosol with consistent, well-characterised properties.
Airflow control
Shaping how air and aerosol move together through each inhalation.
Formulation research
Screening and evaluating formulations designed alongside the device.
Technical specifics remain confidential while development continues.
Current concept · In development
From airflow science to a device you can hold.
The LungSphere concept brings these principles together in a compact, nicotine-free handheld form.
Nicotine-free
Designed around the inhalation experience itself — no nicotine involved.
Detachable mouthpiece
A removable cap protecting the airway inlet between uses.
Dose display
A simple readout of remaining doses, supporting consistent use.
One-hand form
Shaped to sit naturally in the hand during inhalation.
The device is under development. These images show the current concept — it is not a clinically validated or commercially available product.
04 — Development Journey
An honest roadmap from concept to potential application.
Engineering proof of concept
In progressFormulation screening and preclinical evaluation
In progressIntegration of device and formulation
PlannedFuture evaluation of therapeutic applications
Future ambition
05 — Our Vision
A platform for research today and, potentially, therapy tomorrow.
Our long-term ambition is to build an inhalation platform that could first support research into smoking replacement — exploring whether a carefully designed inhalation experience can help address the behavioural side of smoking.
In the future, the same foundations in aerosol and airflow control could potentially enable respiratory drug delivery. Each step will be guided by rigorous science and appropriate regulatory pathways.
06 — Team
The People Behind LungSphere.
Zaid Elhusseini, Ph.D.
Founder & CEO
Respiratory scientist with expertise in pulmonary pathology and translational health.
- Current
- Imperial College London
- Previous
- Harvard Medical School · University of Groningen
Yehya Al-Adwi, Ph.D.
Co-Founder & CSO
Pharmacist and translational scientist specialising in lung inflammation and fibrosis.
- Current
- QPS Netherlands
- Previous
- University of Groningen
Wael Itani, Ph.D.
Engineering Collaborator
Specialising in the design and modelling of thermal-fluid systems for medical devices.
- Current
- American University of Beirut
- Previous
- New York University · Shanghai Jiao Tong University
07 — Contact
Let's Rethink Respiratory Health.
We welcome conversations with research collaborators, strategic partners and investors who share our interest in the future of inhalation.
contact@lungsphere.co.uk